2025³â 07¿ù 12ÀÏ Åä¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Strengthening Healthcare Systems to Meet Patients¡¯ Need for Plasma-Derived Therapies

´º½ºÀÏÀÚ: 2022-09-30

OSAKA, Japan, & GENEVA, Switzerland-- 2022³â 09¿ù 30ÀÏ -- As part of their well-established partnership, the United Nations Institute for Training and Research (UNITAR) and Takeda (TSE:4502/NYSE:TAK), a global pharmaceutical leader and an active member of the United Nations Global Compact, are pleased to announce a new joint initiative focused on strengthening countries’ healthcare systems to meet patients’ need for plasma and plasma-derived therapies. The initiative will draw on UNITAR’s expertise in training and education toward the development of innovative solutions to global challenges and Takeda’s deep knowledge of rare disease and the plasma ecosystem.

Global demand for plasma has greatly increased over the past 20 years and is continuing to grow due to increasing numbers of patients with rare diseases being diagnosed, as well as higher standards of care and broader access to treatment globally. This demand for life-changing and life-sustaining plasma-derived therapies far exceeds available supply, resulting in more people around the world struggling to access the treatments they need, especially in low- and middle-income countries.

The overall goal of this initiative is to create a neutral, UN-based platform that will bring together experts, policymakers, patient organizations, academia, civil society and the private sector. Through increasing awareness, building partnerships and facilitating access to the latest scientific knowledge and best practices, this platform aims to support countries in finding their own tailored solutions on how to improve the quality of life and life expectancy of patients who rely on plasma-derived therapies. The project will also focus on complementing and finding synergies with other existing initiatives to improve plasma ecosystems and increase patient access to care.

The importance of plasma-derived therapies is affirmed by their inclusion in the WHO Model List of Essential Medicines[1], emphasizing their significance for the healthcare system and the need to facilitate access to these products in all countries. Similarly, an increasing number of countries acknowledges the need for - and interest in - strengthening the resilience of their healthcare systems in the field of plasma supply. Pending official confirmation, the pilot phase of the current initiative will be implemented in collaboration with two countries, whose forward-thinking participation in this program to bolster their countries’ health infrastructure around plasma and the patients plasma-derived therapies can help will serve as a pathfinder for potential expansion of the project in the future.

UNITAR will serve as a coordinator of the project, hosting the platform as a collaborative framework for stakeholders to meet, lead informed discussion and lay the groundwork for future collaboration.

"Availability of life-saving and life-sustaining plasma-derived therapies can be a matter of life or death. As part of our mandate within the United Nations System, we will work hand-in-hand with Takeda to build capacity, increase awareness, enhance partnerships and facilitate access to the latest scientific knowledge and best practices in this field,” said Nikhil Seth, UN Assistant Secretary-General and Executive Director of UNITAR. “I am glad to see the partnership between UNITAR and Takeda growing. It can serve as a powerful example of how public-private partnerships can contribute to the goals of the Agenda 2030, and address some of the urgent global challenges, such as ensuring access to health, reducing inequalities, or improving the quality of technical education.”

As a founding sponsor, Takeda will serve as one of the knowledge partners providing plasma expertise, funding and project support.

“We are thrilled to extend Takeda’s established partnership with UNITAR through this new joint initiative to help address the challenges of global plasma supply and provide more plasma-derived therapies to patients who need them,” said Giles Platford, President of Takeda’s Plasma-Derived Therapies Business Unit. “Innovative partnerships that bring together a broad bench of multi-area stakeholders are crucial in strengthening healthcare infrastructure and policy to enable broader access to treatments for people around the world with rare and complex chronic disease.”



 Àüü´º½º¸ñ·ÏÀ¸·Î

Omdia Forecasts Flat TV Shipments in 2025, but Mini LED Poised for Explosive Growth at 82.9%
FDA Approves Gammagard Liquid ERC With Low IgA As First Ready-To-Use Immunoglobulin Therapy
CB Insights Unveils Industry¡¯s First AI Agent Workforce for M&A, Partnerships, Competitive Intelligence, Deal Sourcing, GTM, and More
Altimetrik and SLK Software Join Forces to Create an AI-First Engineering Services Powerhouse
SBC Medical added to membership of Russell 3000¢ç Index
Kinaxis and Tosoh Corporation Formulate an AI-Powered Supply Chain Transformation
Imperva Application Security Integrates API Detection and Response, Setting A New Standard in API Security

 

Groups Representing Patients, Healthcare Professionals and Pharmaceuti...
Zeon & Sino Applied Tech expand SWCNT conductive paste and advance nex...
KnowBe4 Collaborates With Microsoft to Strengthen Email Security Throu...
Thales Launches File Activity Monitoring (FAM) to Strengthen Real-Time...
Expanding Creative Boundaries: LG Taiwan Launches Versatile IT Lineup ...
Galderma Launches Trials of Nemolizumab for Systemic Sclerosis and Chr...
Toshiba Starts Sample Shipments of Second Product in its Smart Motor C...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备: ä¹联êó备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..